Who are Lynparza's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Talzenna, Talzenna, Zejula.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/olaparib.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Lynparza — Competitive Intelligence Brief

Lynparza (olaparib) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Poly(ADP-Ribose) Polymerase Inhibitor [EPC]. Area: Oncology.

marketed Poly(ADP-Ribose) Polymerase Inhibitor [EPC] Poly [ADP-ribose] polymerase 2 Oncology Live · refreshed every 30 min

Target snapshot

Lynparza (olaparib) — AstraZeneca. Lynparza blocks the repair of DNA damage in cancer cells by inhibiting the enzyme PARP.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lynparza TARGET	olaparib	AstraZeneca	marketed	Poly(ADP-Ribose) Polymerase Inhibitor [EPC]	Poly [ADP-ribose] polymerase 2	2014-01-01
Talzenna	talazoparib-tosylate	Pfizer	marketed	Poly(ADP-Ribose) Polymerase Inhibitor	PARP1, PARP2	2018-01-01
Talzenna	talazoparib	Pfizer	marketed	Poly(ADP-Ribose) Polymerase Inhibitor	Poly [ADP-ribose] polymerase 4	2018-01-01
Zejula	niraparib	GSK	marketed	Poly(ADP-Ribose) Polymerase Inhibitor	Poly [ADP-ribose] polymerase 2	2017-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2029-07-27 — Talzenna · 8420650 · US
2029-07-27 — Talzenna · 9820985 · US
2029-07-27 — Talzenna · 10780088 · US
2029-10-19 — Talzenna · 8012976 · US
2031-10-20 — Talzenna · 8735392 · US
2031-10-20 — Talzenna · 10189837 · US

Sponsor landscape (Poly(ADP-Ribose) Polymerase Inhibitor [EPC] class)

AstraZeneca · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lynparza — Competitive Intelligence Brief. https://druglandscape.com/ci/olaparib. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab